New drug combo aims to ease back pain in genetic arthritis
NCT ID NCT06526377
First seen Jan 06, 2026 · Last updated May 08, 2026 · Updated 20 times
Summary
This study tests a new drug called Natrunix, given with standard care, for people with a type of arthritis that affects the spine and joints (axial spondyloarthritis). The trial includes 60 adults who have a specific genetic marker (HLA-B27) and active disease. The goal is to see if Natrunix helps reduce symptoms like pain and stiffness better than a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AXIAL SPONDYLOARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.